Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Meta Expands AI Training With Employee Activity Tracking Tools 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
BASEL, Switzerland and CAMBRIDGE, Mass., May 18, 2017 -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the selection of an abstract for presentation in the Presidential Symposium of the 22nd Congress of the European Hematology Association (EHA) taking place in Madrid, Spain on June 22-25, 2017.
This abstract, selected by the Scientific Program Committee as one of the five best abstracts, will highlight recent work in re-creating the natural condition of hereditary persistence of fetal hemoglobin (HPFH) that is protective in sickle cell disease and beta thalassemia. The presentation will describe the ability to re-create specific HPFH gene variants in the intended target tissue, human primary CD34+ stem cells, the effect of these gene variants at re-creating the expression of protective fetal hemoglobin and progress in developing a product ready for clinical testing.
“We are pleased to have been selected as one of the five best abstracts at the leading global conference in the field of hematology. We remain on track to file a clinical trial application by the end of 2017 and the initiation of clinical trials in Europe in 2018,” said Dr. Rodger Novak, CEO of CRISPR Therapeutics AG.
Details of the presentation are as follows:
| Title: | Re-Creating Hereditary Persistence of Fetal Hemoglobin (HPFH) with CRISPR/Cas9 To Treat Sickle Cell Disease (SCD) and Beta-Thalassemia (Beta-Thal) |
| Presenter: | Bill (Sven Ante) Lundberg, M.D., Chief Scientific Officer, CRISPR Therapeutics |
| Date / Time: | Friday, June 23, 4:00-4:15 PM (Central European time zone) |
| Session Title: | Presidential Symposium located in Hall A |
| Abstract: | S147 |
A copy of the EHA abstracts were made available May 18, 2016 through the EHA meeting website at www.ehaweb.org. Following the presentation, the data presented will be available under the “Investors & Media” section of the Company’s website at www.crisprtx.com and will also be webcast by the EHA.
About CRISPR Therapeutics
CRISPR Therapeutics is a leading gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR / Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. The company's multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Additionally, CRISPR Therapeutics has established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in diseases with high unmet need. The foundational CRISPR / Cas9 patent estate for human therapeutic use was licensed from the company's scientific founder Emmanuelle Charpentier, Ph.D. CRISPR Therapeutics AG is headquartered in Basel, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts. For more information, please visit www.crisprtx.com.
Media Contacts: Jennifer Paganelli WCG on behalf of CRISPR 1-347-658-8290 [email protected] Investor Contact: Chris Brinzey Westwicke Partners for CRISPR 1-339-970-2843 [email protected]
